Studies, research and what the evidence actually says — methods and caveats included.
Sean McKinley of Originals CBD explores the emerging dangers of synthetic and semi-synthetic cannabinoids in Europe, both for businesses and consumers.
In a first-of-its-kind clinical trial, researchers found that people who took THC and CBD had significantly less agitation compared to people who received a placebo.
Inhaled cannabis was associated with ‘large, sustained, and statistically robust improvements’ in pain and disability.
Cannabis-derived molecules could help relieve chronic pain without the psychoactive effects associated with THC.
Researchers say it could help identify those most at risk of developing psychosis.
Researchers have identified a potential mechanism linked to a reduced risk of type 2 diabetes.
ADHD is one of the most commonly reported reasons people seek medical cannabis, but does the evidence support it?
People who consumed THC were more likely to recall words that were never shown to them.
A small pilot study suggests Epidiolex may have benefits for weight restoration and symptom improvement in anorexia patients.
New research suggests that long-term, heavy cannabis use is associated with subtle changes to the brain’s frontal cortex.
By Dr Sue Clenton, Consultant Oncologist and Medical Director at Releaf Cannabis Clinic In her bi-weekly series for Cannabis Health, Dr Sue Clenton, Consultant Oncologist and Medical Director at Releaf […]
Researchers concluded that the available evidence rarely justifies the routine prescribing of cannabinoids for mental health conditions.
Two non-psychoactive cannabis compounds may help treat the most common form of chronic liver disorder.
Upcoming Symposiums
Evidence-led education for clinicians, industry and patient advocates — across Europe.
See all events4 November 2026
Frankfurt · Mainhaus
26 November 2026
London · Conway Hall
